Brought to you by 
Cubist licenses daptomycin from Lilly
11 Apr 2011
Executive Summary
Cubist Pharmaceuticals acquired exclusive rights to Eli Lilly's Phase II daptomycin to treat diseases caused by Staphylococcus aureus and enterococcus bacteria. Financial terms include a license fee, milestone payments, and royalties.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist licenses daptomycin from Lilly
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice